ICCS 2026 puts therapy-aware flow reagents in focus: CD38(VHH) JK36 and TRBC2

The ICCS poster list includes work on anti-CD38(VHH) conjugates after CD38-directed therapies and on TRBC1/TRBC2 conjugates for T-cell clonality assessment. Current catalogue records identify JK36/C94642 as CD38(VHH)-Alexa Fluor 488, 50 tests, liquid, RUO; and SAM.2/D06177 as TCR Cβ2 (TRBC2)-APC, 50 tests, liquid, RUO.

CFCM explainer

Therapy or clonality question → conventional phenotype can become ambiguous → targeted epitope/clonality reagent may improve interpretability.

Source/credit: CFCM conceptual explainer based on primary product pages and ICCS poster titles. Alt text: therapy-aware reagent decision path.

The event page lists poster titles but not sufficient performance data to assess sensitivity, specificity, interference or clinical utility. Beckman's statement that JK36 recognizes an epitope not masked by daratumumab is a manufacturer product claim; RUO status must remain explicit.

Post-therapy panel design increasingly depends on reagents that remain interpretable after target-directed treatment. JK36 illustrates a therapy-aware reagent strategy: use an analytical epitope intended to remain accessible when conventional anti-CD38 epitopes are occupied. For T-cell clonality, TRBC1/TRBC2 adds another targeted interpretive strategy. CFCM publishes this as WATCH: the reagents and RUO status are verified, while clinical performance and utility require broader independent evidence.